Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;37(7):2143-2161.
doi: 10.1007/s11011-022-00999-2. Epub 2022 May 10.

Emerging targets signaling for inflammation in Parkinson's disease drug discovery

Rhema Chandan Khairnar  1 , Niraj Parihar  1 , Kedar S Prabhavalkar  1 , Lokesh Kumar Bhatt  2
Affiliations
Review

Emerging targets signaling for inflammation in Parkinson's disease drug discovery

Rhema Chandan Khairnar et al. Metab Brain Dis. 2022 Oct.

Abstract

Parkinson's disease (PD) patients not only show motor features such as bradykinesia, tremor, and rigidity but also non-motor features such as anxiety, depression, psychosis, memory loss, attention deficits, fatigue, sexual dysfunction, gastrointestinal issues, and pain. Many pharmacological treatments are available for PD patients; however, these treatments are partially or transiently effective since they only decrease the symptoms. As these therapies are unable to restore dopaminergic neurons and stop the development of Parkinson's disease, therefore, the need for an effective therapeutic approach is required. The current review summarizes novel targets for PD, that can be utilized to identify disease-modifying treatments.

Keywords: Abelson protein; Cocaine-amphetamine regulated transcript; GSK-3β; LRRK2; Microglial NLRP3, Th17 cells; Parkinson’s disease.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Abushouk AI, Negida A, Elshenawy RA et al (2017) C-Abl Inhibition; A Novel Therapeutic Target for Parkinson’s Disease. CNS Neurol Disord - Drug Targets. https://doi.org/10.2174/1871527316666170602101538 - DOI - PubMed
    1. Ahmed S, Kwatra M, Ranjan Panda S et al (2021) Andrographolide suppresses NLRP3 inflammasome activation in microglia through induction of parkin-mediated mitophagy in in-vitro and in-vivo models of Parkinson disease. Brain Behav Immun 91:142–158. https://doi.org/10.1016/j.bbi.2020.09.017 - DOI - PubMed
    1. AlDakheel A, Kalia LV, Lang AE (2014) Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease. Neurotherapeutics 11:6–23. https://doi.org/10.1007/s13311-013-0218-1 - DOI - PubMed
    1. Brahmachari S, Ge P, Lee SH et al (2016) Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration. J Clin Invest. https://doi.org/10.1172/JCI85456 - DOI - PubMed - PMC
    1. Brahmachari S, Karuppagounder SS, Ge P et al (2017) c-Abl and Parkinson’s Disease: Mechanisms and Therapeutic Potential. J Parkinsons Dis 7:589–601. https://doi.org/10.3233/JPD-171191 - DOI - PubMed - PMC

LinkOut - more resources